Study of Early Intranasal Cooling After Out-of-Hospital Cardiac Arrest Compared to Standard Treatment For Adults Aged 18 to 79 Years With Shockable Heart Rhythm

What this Trial Is About

Researchers are evaluating the impact of ultra-early transnasal evaporative cooling after cardiac arrest compared to the current recommended normothermia. This trial focuses on adults aged 18 to 79 who experienced out-of-hospital cardiac arrest with an initial shockable rhythm. The goal is to determine if early cooling improves survival with complete neurological recovery at 90 days post-arrest. Participants are randomly assigned to one of two groups. The intervention group receives early transnasal evaporative cooling started by EMS personnel at the scene within 20 minutes of arrival, followed by systemic hypothermia at 33C for 24 hours and fever control for 72 hours in the ICU. The control group receives standard advanced cardiac life support and normothermia with fever control for 72 hours in the ICU. During the study, researchers will monitor survival rates and neurological outcomes at 90 days using the modified Rankin scale. Secondary measures include return of spontaneous circulation, survival at hospital discharge, and adverse event rates. Participants will be closely observed from the time of cardiac arrest through hospital treatment and follow-up to assess the effectiveness and safety of the cooling treatment compared to standard care.

Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2